Podcast

April 14, 2018

Podcast: This Week in Managed Care—Work Requirements for Benefits and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care^® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included President Donald Trump signing an executive order requiring the poor to get jobs or lose food and healthcare benefits; a CMS report found ethnic, racial, and gender disparities in Medicare Advantage plans; CDC highlighted the impact of HIV on America's youth.

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Listen above or through one of these podcast services:

What We're Reading: Trump Signs Executive Order; VA Staffing Crisis; Texas Hospital Firm Draws Scrutiny

CMS Creates New ACA Penalty Mandate Exemptions, Including Opposition to Abortion

CMS Report Details Extent of Medicare Advantage Racial, Gender Disparities

Sanofi to Start Offering Discounts on Two Insulin Products

National Youth HIV/AIDS Awareness Day: Highlighting the Impact of Disease on the Age Group

With the Oncology Care Model, "Everyone Has to Be Engaged," Including Patients

Read more about the stories in this podcast:

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

CK Wang, MD, COTA

Eric Lander, MD

Eric Lander, MD

Gordon Crofoot, MD, PA

David Awad, PharmD, BCOP

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center

Related Content

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

David Nguyen, MD | Image Credit: Tufts Medicine

July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

AJMC

July 23rd 2025

Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive Disorder

Nadia Nabulsi, PhD François Laliberté, MA Enrico Zanardo, PhD Sean D. MacKnight, MScPH Sophie Ma, MSc Sally W. Wade, MPH Mousam Parikh, MSc

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

July 23rd 2025

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

AJMC Contributor

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

Related Content

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

David Nguyen, MD | Image Credit: Tufts Medicine

July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

AJMC

July 23rd 2025

Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive Disorder

Nadia Nabulsi, PhD François Laliberté, MA Enrico Zanardo, PhD Sean D. MacKnight, MScPH Sophie Ma, MSc Sally W. Wade, MPH Mousam Parikh, MSc

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

July 23rd 2025

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

AJMC Contributor

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions